Michael Korn - Concepedia

Author

Michael Korn

Caris Life Sciences (United States)

Also Known As

M Korn, M. Korn, Maximilian Korn, Michael Korn

Publications

548

Citations

H-Index

Concepts

All Affiliations

Caris Life Sciences (United States)The Barbara Ann Karmanos Cancer Institute Fondazione IRCCS Istituto Nazionale dei Tumori University of California, San Francisco University of Southern California

About

Michael Korn is an author at Caris Life Sciences (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	418
2	Gastroenterology	2	2	173
3	Cell Biology	1	1	30
4	Clinical Immunology	1	1	10
5	Immunology	1	1	10

Michael Korn

Publications

516

Citations

H-Index

Page 1

	Year	Citations
Gastric Cancer Jaffer A. Ajani, James S. Barthel, Tanios Bekaii‐Saab, Journal of the National Comprehensive Cancer Network New StandardEsophageal CancerEndoscopic ImagingGastrointestinal OncologyMedicine	2010	159
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications Roberto Moretto, Andrew Elliott, Jian Zhang, JNCI Journal of the National Cancer Institute	2021	72
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer U. Klaassen, H. Wilke, Dirk Strumberg, European Journal of Cancer Breast OncologyOncologyMedicineGynecologyBreast Cancer	1996	70
Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors Alan P. Venook, Amy Ko, Margaret A. Tempero, Journal of Clinical Oncology Progressive Neuroendocrine TumorsPathologyPharmacotherapyTumor BiologyNeuro-oncology	2008	52
Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells Garret Yount, Golnar Afshar, Stefan Ries, Oncogene Neuro-oncologyTranscriptional ActivationGliomaOncogenic AgentGlioma Cells	2001	30
Who gets radiotherapy? Maher Ej, Stanley Dische, E N Grosch, PubMed Adaptive RadiotherapyPalliative CareRadiation MedicineTherapy GuidelinesCurative Therapy	1990	26
A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer A. Harstrick, Hans‐Joachim Wilke, Wilfried Eberhardt, Oncology Research and Treatment Intravenous TreosulfanOncologyDose Escalation TrialMedicineStem-cell Reinfusion	1996	24
Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. Kent C. Shih, Johanna C. Bendell, Anne Reinert, Journal of Clinical Oncology Torc2 BiomarkersPathologyPharmacotherapyTumor BiologyMolecular Pharmacology	2012	20
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer U. Klaassen, H. Wilke, Regina Weyhofen, Anti-Cancer Drugs	1998	14
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. H. Wilke, Michael Korn, U. Vanhöfer, PubMed OncologyGastrointestinal OncologyAdvanced Gastric CancerMedicineGastroenterology	1996	14

Page 1